Delving into the Latest Updates on Chengdu Push Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

CD11a(Leukocyte adhesion glycoprotein LFA-1 alpha)	1

主要目的：比较成都康弘药业集团股份有限公司研制的立他司特滴眼液与Xiidra®在健康受试者中单次给药后泪液中的药代动力学特征。次要目的：比较立他司特滴眼液与Xiidra®在健康受试者中单次给药后血浆中的药代动力学特征；观察立他司特滴眼液在健康受试者中单次给药的安全性。

[Translation]

Primary objective: To compare the pharmacokinetic characteristics of lifalast eye drops developed by Chengdu Kanghong Pharmaceutical Group Co., Ltd. and Xiidra® in tears after a single dose in healthy subjects. Secondary objective: To compare the pharmacokinetic characteristics of lifalast eye drops and Xiidra® in plasma after a single dose in healthy subjects; to observe the safety of a single dose of lifalast eye drops in healthy subjects.

Start Date21 Aug 2024

Sponsor / Collaborator

Chengdu Push Pharmaceutical Co., Ltd.

[+1]

CTR20223045 / CompletedPhase 1

立他司特滴眼液在健康受试者体内的安全性及药代动力学特征的临床试验

[Translation] Clinical trial on the safety and pharmacokinetic characteristics of lifalast eye drops in healthy subjects

主要目的：评价立他司特滴眼液在中国健康受试者中给药后的药代动力学特征。次要目的：评价立他司特滴眼液在中国健康受试者中给药后的安全性。

[Translation]

Primary objective: To evaluate the pharmacokinetic characteristics of lifalast eye drops after administration in healthy Chinese subjects. Secondary objective: To evaluate the safety of lifalast eye drops after administration in healthy Chinese subjects.

Start Date01 Feb 2023

Sponsor / Collaborator

Chengdu Push Pharmaceutical Co., Ltd.

[+1]

CTR20213119 / RecruitingPhase 3

立他司特滴眼液用于治疗干眼症的有效性和安全性的多中心、随机、双盲、安慰剂对照的 III 期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial on the efficacy and safety of lifalast eye drops in the treatment of dry eye

通过测量在治疗 84 天后，试验组和安慰剂组下角膜荧光素染色评分（ICSS）较基线的改变均值，评估立他司特滴眼液与安慰剂相比在改善干眼症（DED）体征方面的疗效。

[Translation]

The efficacy of lisdenafil eye drops in improving signs of dry eye disease (DED) compared with placebo was evaluated by measuring the mean change from baseline in the corneal fluorescein staining score (ICSS) in the experimental group and the placebo group after 84 days of treatment.

Start Date17 Feb 2022

Sponsor / Collaborator

Chengdu Push Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Chengdu Push Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Chengdu Push Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Chengdu Push Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Chengdu Push Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Other

Login to view more data